Philippines to look into bribery claim vs Sinovac

Kristine Sabillo, ABS-CBN News

<figure class="op-interactive"><iframe height="315" src="https://www.youtube.com/embed/9xj1nimN4zM?enablejsapi=1" width="560"></iframe></figure><div class="iwantbar">Watch more in <a href="//www.iwantv.com.ph/">iWantv</a> or <a href="//tfc.tv/">TFC.tv</a></div>MANILA — The Department of Health on Wednesday said the country’s vaccine panels will look into reports that Chinese vaccine manufacturer Sinovac bribed Chinese drug regulators before.A Washington Post <a href="https://www.washingtonpost.com/world/asia_pacific/coronavirus-vaccine-china-bribery-sinovac/2020/12/04/7c09ae68-28c6-11eb-9c21-3cc501d0981f_story.html">report </a>said court records show that Sinovac, which is also applying to run COVID-19 vaccine clinical trials in the Philippines, acknowledged the bribery. The CEO of the company reportedly told the court that he could not refuse the regulatory official who demanded for money.Health Secretary Francisco Duque III said the agency is aware of the media report.“This will also form part of the work of the vaccine expert panel. They will assess the veracity first and foremost of such a report. Kung meron mang katotohanan ito (If there is some truth to this),” he said during a virtual briefing.Duque said there is also a possibility that the source of the media report was questionable. “The prudent thing to do is to investigate and to validate. If true, it’s up to the vaccine expert panel to include this in the report and also FDA,” he said.The health chief explained that such issues are the reason why there is an ethics review board as well. He said the board should ensure that the country does not enter questionable transactions in case the corruption claim against Sinovac is true.According to the Washington Post report, Sinovac was about to run clinical trials of a SARS vaccine and a swine flu vaccine in 2003 and 2009, respectively, when the bribery charges were made. The company’s CEO admitted to giving more than $83,000 to a regulatory official from 2002 to 2011. In return, Sinovac’s vaccine certifications were reportedly expedited.While no safety concerns have yet been raised against Sinovac, experts interviewed by the Washington Post said such corruption charges may cast a “shadow of doubt” on the company’s vaccine claims.Sinovac is one of the dozen or so companies that have already reached Phase 3 clinical trials. It’s application for clinical trials in the Philippines has already been approved by the vaccine expert panel. It is still awaiting clearance by the ethics review board before it can be officially evaluated by the Food and Drug Administration.

MANILA — The Department of Health on Wednesday said the country’s vaccine panels will also look into reports that Chinese vaccine manufacturer Sinovac resorted bribing drug regulators before.

MANILA — The Department of Health on Wednesday said the country’s vaccine panels will also look into reports that Chinese vaccine manufacturer Sinovac resorted bribing drug regulators before.

Philippines to look into bribery claim vs Sinovac | ABS-CBN

Halalan 2025

Entertainment

News

Metro.Style

Sports

More

Traffic

News

Philippines to look into bribery claim vs Sinovac

Philippines to look into bribery claim vs Sinovac

Kristine Sabillo,

ABS-CBN News

Published Dec 09, 2020 01:25 PM PHT

|

Updated Dec 09, 2020 01:33 PM PHT

Read More:

COVID-19 vaccine

Sinovac

Chinese COVID-19 vaccine

Department of Health

Food and Drug Administration

ABS-CBN is the leading media and entertainment company in the Philippines, offering quality content across TV, radio, digital, and film. Committed to public service and promoting Filipino values, ABS-CBN continues to inspire and connect audiences worldwide.

Corporate

Investors

Governance

International Distribution

Corporate

Governance

Investors

International Distribution

NPC Seal of Registration

Privacy Policy

Terms of Service

Advertise with Us

© 2025 ABS-CBN Corporation. All Rights Reserved.

NPC Seal of Registration

Advertise with Us

Privacy Policy

Terms of Service

© 2025 ABS-CBN Corporation. All Rights Reserved.